Dexcom Director Files Intent to Sell $218K in Stock (DXCM)
DEXCOM INC
Subscribe to track DXCM
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Dexcom Director Files Intent to Sell $218K in Stock (DXCM)
Company: DEXCOM INC (DXCM) Form: 144 | Filed: 2025-11-10 Significance: Low
Insider: Collins Richard Alexander Title: Director | Relationship: Director
Transaction: • Type: Proposed Sale • Shares: 3,948 • Value: $217,811
Key Insight: A director has filed a notice of proposed sale for a small amount of stock, representing a negligible fraction of the company's market capitalization. The sale was arranged under a pre-adopted trading plan.
Market Context: The transaction value is approximately 0.001% of Dexcom's $21.45B market cap, indicating a routine, non-material event for the company.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: DEXCOM INC (DXCM)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A director filed a notice of a proposed sale of shares valued at approximately $218k, a transaction of minimal financial significance to the company.
- Market Impact: The sale is too small to have any meaningful impact on the stock price or market sentiment.
Company Information
| Field | Value |
|---|---|
| Company | DEXCOM INC |
| Ticker Symbol | DXCM |
| CIK | 0001093557 |
| Industry | Surgical & Medical Instruments & Apparatus |
Insider Information
| Field | Value |
|---|---|
| Name | Collins Richard Alexander |
| CIK | 0001700619 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 |
| Transaction Date | 2025-11-10 |
| Transaction Code | S (Proposed Sale) |
| Security Type | Common Stock |
| Shares Involved | 3,948 |
| Price Per Share | $55.17 |
| Total Value | $217,811.16 |
| Shares Owned After | Not Available |
| Ownership Type | Indirect (via Trust) |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $217,811.16 |
| % of Market Cap | 0.001% |
| Shares Transacted | 3,948 |
| % of Shares Outstanding | 0.001% |
| Post-Transaction Ownership | Not Available |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The $218k transaction is negligible compared to Dexcom's $21.45 billion market capitalization.
- Transaction Significance: The sale represents a tiny fraction of both the market cap (0.001%) and shares outstanding (0.001%), categorizing it as a routine financial management activity by the insider rather than a strategic move.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction size is immaterial and is unlikely to influence investor perception or stock price.
Volume & Sentiment
- Expected Volume Impact: None. The number of shares is too small to affect trading volume.
- Sentiment Indicator: Neutral. This filing does not provide any new information that would shift market sentiment.
Additional Context
Transaction Notes
- Special Circumstances: The filing notes a plan adoption date of August 7, 2025, indicating this is a pre-planned sale, likely under a Rule 10b5-1 trading plan. This reduces the significance of the sale as it was not based on immediate market conditions.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.